1. Antoun Reyad A, Girgis E, Mishriky R. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: A meta-analysis of randomized controlled trials. International Clinical Psychopharmacology. Lippincott Williams and Wilkins, 2020, p. 119–28.
2.
Arango C, Ng-Mak D, Finn E, Byrne A, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: A systematic literature review and network meta-analysis. Eur Child Adolesc Psychiatry 2020 Sep 1; 29(9): 1195–205.
3.
Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. Vol. 269, Journal of Affective Disorders, Elsevier B.V. 2020, p. 154–84.
4.
Barabássy Á, Sebe B, Acsai K, Laszlovszky I, Szatmári B, Earley WR, et al. Safety and tolerability of cariprazine in patients with schizophrenia: A pooled analysis of eight phase II/III studies. Neuropsychiatr Dis Treat 2021; 17: 957–70.
5.
Brown ES, Khaleghi N, van Enkevort E, Ivleva E, Nakamura A, Holmes T, et al. A pilot study of brexpiprazole for bipolar depression. J Affect Disord 2019; 249: 315–18.
6.
Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: A phase 3 randomized placebo-controlled trial. American Journal of Psychiatry 2021; 178(12): 1098–106.
7.
Calabrese JR, Keck PE, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose Cariprazine in acute and mixed mania associated with bipolar I disorder: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2015 Mar 1; 76(3): 284–92.
8.
Charoensook J, Maguire GA. A case series on the effectiveness of lurasidone in patients with stuttering. Ann Clin Psychiatry 2017 Aug; 29(3): 191–4.
9.
Citrome L. Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Vol. 9, Expert Opinion on Drug Metabolism and Toxicology 2013, p. 193–206.
10.
Citrome L. Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Prefer Adherence, 2016.
11.
Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be hel. Int J Clin Pract 2015; 69, 978–997.
12.
Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: Results from a randomized, exploratory study. Int Clin Psychopharmacol 2016; 31(4): 192–201.
13.
Citrome L, Ouyang J, Shi L, Meehan SR, Baker RA, Weiss C. Effect of brexpiprazole on agitation and hostility in patients with schizophrenia: Post hoc analysis of short- and long-term studies. J Clin Psychopharmacol 2019; 39(6): 597–603.
14.
Citrome L, Stensbøl TB, Maeda K. The preclinical profile of brexpiprazole: What is its clinical relevance for the treatment of psychiatric disorders? Vol. 15, Expert Review of Neurotherapeutics. Taylor and Francis Ltd., 2015, p. 1219–29.
15.
Citrome L, Yatham LN, Patel MD, Barabássy Á, Hankinson A, Earley WR. Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. J Affect Disord 2021; 288: 191–8.
16.
Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Vol. 29, European Neuropsychopharmacology. Elsevier B.V. 2019, p. 971–85.
17.
Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, et al. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: Indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat 2019; 15: 2537–50.
18.
Correll CU, Vanover KE, Davis RE, Chen R, Satlin A, Mates S. Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr Res 2021; 228: 198–205.
19.
Davis LL, Ota A, Perry P, Tsuneyoshi K, Weiller E, Baker RA. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav 2016; 6(10).
20.
Davis RE, Correll CU. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes. Expert Rev Neurother 2016; 16(6): 601–14.
21.
Delbello MP, Tocco M, Pikalov A, Deng L, Goldman R. Tolerability, safety, and effectiveness of two years of treatment with lurasidone in children and adolescents with bipolar depression. J Child Adolesc Psychopharmacol 2021 Sep 1; 31(7): 494–503.
22.
Derry S, Andrew RA. Atypical antipsychotics in bipolar disorder: Systematic review of randomised trials. BMC Psychiatry 2007; 7: 40.
23.
Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2009.
24.
Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Németh G, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. American Journal of Psychiatry 2016; 173(3): 271–81.
25.
Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2015; 17(1): 63–75.
26.
Earley W, Durgam S, Lu K, Ruth A, Németh G, Laszlovszky I, et al. Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. J Affect Disord 2018; 226: 239–44.
27.
Earley W, Guo H, Daniel D, Nasrallah H, Durgam S, Zhong Y et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data. Schizophr Res 2019; 204: 282–288.
28.
Ferrari A J, Santomauro DF. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022; 9: 137–150.
29.
Freeman MP, Fava M, Dirks B, Jha MK, Papakostas GI, Shelton RC, et al. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depress Anxiety 2020 May 1; 37(5): 485–95.
30.
Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022 Feb 1; 9(2): 137–50.
31.
Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in alzheimer’s dementia: Two 12-week, randomized, double-blind, placebo-controlled trials. American Journal of Geriatric Psychiatry 2020; 28(4): 383–400.
32.
Gupta M, Hoover G. Lurasidone an effective alternative for the treatment of irritability associated with autism spectrum disorder. Cureus 2020.
33.
Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. European Neuropsychopharmacology 2013; 23: 1373–82.
34.
El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry 2006; 189: 102-8.
35.
Ichinose M, Miura I, Horikoshi S, Yamamoto S, Kanno-Nozaki K, Watanabe K et al. Effect of switching to brexpiprazole on plasma homovanillic acid levels and antipsychotic-related side effects in patients with schizophrenia or schizoaffective disorder. Neuropsychiatr Dis Treat 2021; 17: 1047–53.
36.
Ishigooka J, Inada K, Niidome K, Aoki K, Kojima Y, Iwashita S et al. Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study. Hum Psychopharmacol 2021: 36.
37.
Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci 2018; 72(9): 692–700.
38.
Ivanov SV, Smulevich AB, Voronova EI, Yakhin KK, Beybalaeva TZ, Katok AA. Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study). Front Psychiatry 2022; 12.
39.
Ivkovic J, Lindsten A, George V, Eriksson H, Hobart M. Effect of brexpiprazole on prolactin: An analysis of short- and long-term studies in schizophrenia. J Clin Psychopharmacol. 2019; 39(1): 13–9.
40.
Kadakia A, Dembek C, Heller V, Singh R, Uye J, Hagi K. et al. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry 2021; 21.
41.
Kane JM, Durgam S, Satlin A, Vanover KE, Chen R, Davis R, et al. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo-and active-controlled clinical trials. Int Clin Psychopharmacol 2021; 36(5): 244–50.
42.
Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, et al. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res 2016; 174(1–3): 93–8.
43.
Kearns B, Cooper K, Cantrell A, Thomas C. Schizophrenia treatment with second-generation antipsychotics: A multi-country comparison of the costs of cardiovascular and metabolic adverse events and weight gain. Neuropsychiatr Dis Treat 2021; 17: 125–137.
44.
Ketter TA, Sachs GS, Durgam S, Lu K, Starace A, Laszlovszky I, et al. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study. J Affect Disord 2018; 225: 350–6.
45.
Kiss B, Horváth A, Némethy Z, Schmidt É, Laszlovszky I, Bugovics G, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D 3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile. Journal of Pharmacology and Experimental Therapeutics 2010; 333(1): 328–40.
46.
Krystal AD, Zammit G. The sleep effects of lurasidone: a placebo-controlled cross-over study using a 4-h phase-advance model of transient insomnia. Human Psychopharmacology: Clinical and Experimental 2016 May; 31(3): 206–16.
47.
Laszlovszky I, Barabássy Á, Németh G. Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: Pharmacology, efficacy, and safety. Vol. 38, Advances in Therapy. Adis 2021, p. 3652–73.
48.
Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. Journal of Pharmacology and Experimental Therapeutics. 2014; 350(3): 589–604.
49.
Mattingly GW, Haddad PM, Tocco M, Xu J, Phillips D, Pikalov A et al. Switching to Lurasidone following 12 months of treatment with Risperidone: Results of a 6-month, open-label study. BMC Psychiatry 2020; 20.
50.
Mauri MC, Paletta S, di Pace C, Reggiori A, Cirnigliaro G, Valli I, et al. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Vol. 57, Clinical Pharmacokinetics. Springer International Publishing, 2018, p. 1493–528.
51.
McIntyre RS, Masand PS, Earley W, Patel M. Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials. J Affect Disord 2019; 257: 600–6.
52.
Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: Analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr 2015; 20: 140–7.
53.
Nuñez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. Journal of Affective Disorders. Elsevier B.V. 2022, p. 385–400.
54.
O’Connor M. Adjunctive therapy with brexpiprazole improves treatment resistant complex post traumatic stress disorder in domestic family violence victims. Australasian Psychiatry 2020; 28(3): 264–6.
55.
Orsolini L, de Berardis D, Volpe U. Up-to-date Expert Opinion on the safety of recently developed antipsychotics. Expert Opinion on Drug Safety. Taylor and Francis Ltd 2020.
56.
Podwalski P, Samochowiec J. Neuroscience-based Nomenclature – a paradigm shift in the classification of psychiatric drugs. Pharmacotherapy in Psychiatry and Neurology 2022; 38(1): 35–47.
57.
Sabe M, Zhao N, Crippa A, Kaiser S. Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials. Vol. 7, npj Schizophrenia 2021; 7.
58.
Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo-controlled, phase III trial. J Affect Disord 2015; 174: 296–302.
59.
Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis. Vol. 13, Expert Opinion on Drug Discovery. Taylor and Francis Ltd 2018, p. 103–10.
60.
Saraf G, Pinto JV, Yatham LN. Efficacy and safety of cariprazine in the treatment of bipolar disorder. Expert Opin Pharmacother. 2019; 20(17): 2063–72.
61.
Sasabe H, Koga T, Furukawa M, Matsunaga M, Sasahara K, Hashizume K, et al. In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. Xenobiotica 2021; 51(5): 522–35.
62.
Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, et al. Blood levels to optimize antipsychotic treatment in clinical practice: A joint consensus statement of the American society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft für neuropsychopharmakologie und pharmakopsychiatrie. Journal of Clinical Psychiatry. 2020; 81(3).
63.
Sebe B, Barabássy Á, Acsai K, Laszlovszky I, Dombi ZB, Vass G, et al. The effect of cariprazine on agitation and hostility in patients with schizophrenia: post-hoc analysis European Neuropsychopharmacology [Internet] 2020 Nov; 40: S327–8. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0924977X20306957
64.
Siwek M, Gorostowicz A. Lurasidone in therapy of treatment-resistant ultra-rapid cycling bipolar disorder: Case report. Clinical Psychopharmacology and Neuroscience 2021 Aug 1; 19(3): 568–71.
65.
Siwek M, Krupa AJ, Wasik A. Lurasidon – właściwości farmakodynamiczne i farmakokinetyczne, potencjał kliniczny i ryzyko interakcji. 2020 [cited 2022 Nov 28]; Available from: https://doi.org/10.33450/fpn.2020.06.002 (a)
66.
Siwek M, Wasik A, Krupa A, Gorostowicz A. Nowe leki przeciwpsychotyczne. Medical Education 2020. (b)
67.
Siwek M, Wojtasik-Bakalarz K, Leki przeciwpsychotyczne. W: Rybakowski J. Psychofarmakologia Kliniczna. Wydawnictwo Naukowe PWN, Warszawa 2022.
68.
Snyder GL, Vanover KE, Davis RE, Li P, Fienberg A, Mates S. A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia. In: Advances in Pharmacology. Academic Press Inc. 2021, p. 253–76.
69.
Srisurapanont M, Suttajit S, Likhitsathian S, Maneeton B, Maneeton N. A network meta-analysis of the dose-response effects of lurasidone on acute schizophrenia. Sci Rep 2021 Dec 1; 11(1).
70.
Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo. J Clin Psychiatry 2013; 74: 507–15.
71.
Syed AB, Brašić JR. The role of lumateperone in the treatment of schizophrenia. Ther Adv Psychopharmacol 2021 Jan; 11: 204512532110340.
72.
Szatmári B, Barabássy Á, Harsányi J, Laszlovszky I, Sebe B, Gál M, et al. Cariprazine safety in adolescents and the elderly: Analyses of clinical study data. Front Psychiatry 2020; 11.
73.
Tariot PN, Cummings JL, Soto-Martin ME, Ballard C, Erten-Lyons D, Sultzer DL, et al. Trial of pimavanserin in dementia-related psychosis. New England Journal of Medicine 2021 Jul 22; 385(4): 309–19.
74.
Thase ME, Zhang P, Weiss C, Meehan SR, Hobart M. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opin Pharmacother 2019; 20: 1907–1916.
75.
Titulaer J, Radhe O, Danielsson K, Dutheil S, Marcus MM, Jardemark K, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. European Neuropsychopharmacology 2022; 62: 22–35.
76.
Watanabe Y, Yamada S, Otsubo T, Kikuchi T. Brexpiprazole for the treatment of schizophrenia in adults: An overview of its clinical efficacy and safety and a psychiatrist’s perspective. Drug Des Devel Ther 2020; 14: 5559–74.
77.
Wichniak A, Samochowiec J, Szulc A, Dudek D, Heitzman J, Janas-Kozik M, et al. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders. Psychiatr Pol 2021; 55(5): 941–66.
78.
Zheng W, Cai D bin, Yang XH, Li L, Zhang QE, Ng CH, et al. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials. Journal of Psychiatric Research. Elsevier Ltd 2018, p. 244–51.
